bioRxivImmunologyPreprint
Glucose-Fueled Histone Modifications Drive HIV-1 Latency Reversal at Hypoxia
Yetunde I. KayodeiD, Deanna C. Clemmer, Adebola A. Owolabi, AbdulKareem A. AlShaheeb, Elyse K. McMahoniD, Anna Tangiyan, Lauren Clark, Glenn E. Simmons, Alberto BosqueiD, Melanie R. McReynoldsiD, Harry E. TayloriD
Abstract
The major barrier to curing HIV-1 infection is the persistence of a latent reservoir in CD4 T cells within tissues which readily fuel viral rebound upon antiretroviral therapy (ART) interruption. Clinical trials aimed at purging these viral reservoirs with latency reversal agents (LRAs) have been unsuccessful owing to our incomplete understanding of the molecular and physiological determinants that underlie latency reversal in these virus-harboring tissues. Here, using a combination of complementary pharmacological and metabolomic approaches, we uncover glucose as a conditionally essential nutrient for HIV-1 latency reversal at hypoxic conditions. By modelling physiological variations in both glucose and oxygen availability as found in vivo within tissues that may harbor the HIV reservoir, we show that hyperglycemic conditions potentiate HIV-1 latency reversal. Importantly, we found major classes of clinically relevant LRAs, PKC agonists (PKCags) and histone deacetylase inhibitors (HDACis) have disparate efficacies under glucose-limiting conditions. Mechanistically, we show that this differential glycolytic dependency is due to distinct capacities of LRAs to induce glycolytic flux during adaptation to hypoxia, a condition that increases glycolytic dependence. Furthermore, we show that PKCag-induced glycolysis drives histone lactylation, a post-translational modification (PTM) we found to be associated with HIV-1 latency reversal and promotes increased chromatin accessibility at the HIV promoter. Importantly, we identify KAT2A as a lactyl-transferase critical for histone lactylation induced upon latency reversal. Taken together, our findings uncover glucose and oxygen availability as critical metabolic determinants of HIV-1 latency reversal and underscore the importance of modeling physiologically relevant experimental conditions in vitro aimed at identifying therapeutic agents that effectively target the latent reservoir in vivo.
- organism: human
- assay: ChIP-seq
- assay: metabolomics
- research focus: chromatin & epigenetic regulation
- research focus: host-pathogen & immune response
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress
I. L. Shytaj, F. A. Procopio, … A. Savarino·bioRxiv·Dec 30, 2020
- A truncated HIV Tat demonstrates potent and specific latency reversal activity
E. Van Gulck, M. Pardons, … D. Boden·bioRxiv·Mar 2, 2023
- Hydrogen sulfide blocks HIV rebound by maintaining mitochondrial bioenergetics and redox homeostasis
V. K. Pal, R. Agrawal, … A. Singh·bioRxiv·Apr 21, 2021
- Type I interferons sensitise HIV-1-reactivating T-cells for NK cell-mediated elimination despite HDACi-imposed dysregulation of innate immunity
J. Prigann, D. Postmus, … C. GOFFINET·bioRxiv·May 4, 2020
- CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T-cells
Riley M. Horvath, Ivan Sadowski·iSciencePeer-reviewed·Oct 30, 2024
- Rev-RRE activity modulates HIV-1 replication and latency reactivation: Implications for viral persistence and cure strategies
Godfrey A. Dzhivhuho, Patrick Jackson, … David M. Rekosh·PLoS PathogensPeer-reviewed·May 15, 2025